Genitourinary Cancer in 2021 and Beyond
Expert perspectives and strategic insights on the latest therapeutic developments and translational research in genitourinary cancer treatment. Topics include clinical decision-making and the extent to which emerging data will affect ongoing research, development of new compounds, and future treatment paradigms.
FACULTY CHAIR
Daniel Petrylak, MD
Yale University, New Haven, CT, USA
Faculty Members
David Quinn, MBBS, PhD, FRACP, FACP
University of Southern California, Los Angeles, CA, USA
Oliver Sartor, MD
Tulane University School of Medicine, New Orleans, LA, USA
Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center, Charlottesville, VA, USA
Bernard H. Bochner, MD, FACS
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Leonard Gomella, MD, FACS
Thomas Jefferson University, Philadelphia, PA, USA
Scott Tagawa, MD, FACP
Weill Cornell Medicine, New York, NY, USA
David Nanus, MD
Weill Cornell Medicine, New York, NY, USA
Susan Slovin, MD, PhD, FACP
Memorial Sloan Kettering Cancer Center, New York, NY, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
The report was based on the following topics
- Advances in Imaging Technologies for GU Cancers
- Diagnosing and Managing Localized/Locally Advanced Prostate Cancer
- Treatment Paradigms for Advanced Prostate Cancer
- Investigational Therapies for Metastatic CRPC
- Early Stage Bladder Cancer (BCG-Resistant NMIBC; MIBC)
- Current Paradigms and Future Directions in Metastatic Bladder Cancer
- Evolving Paradigms for Metastatic RCC
- Neo/Adjuvant Treatment of RCC
- Current and Future Management of Non-clear Cell RCC
